Vitamin D: a new hope for chronic kidney disease?
Vitamin D analogs may slow the progression of chronic kidney disease. Tan et al. report that paricalcitol has additive effects with an angiotensin-converting enzyme inhibitor (ACEI) in suppressing extracellular matrix expression, interstitial inflammation, and myofibroblast activation in obstructive nephropathy. Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS). Vitamin D analogs may enhance the renoprotective effects of RAS inhibitors.
Li
Min
M
Section of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, Section of Nephrology and Hypertension, New Orleans, Louisiana 70112, USA. minlee@tulane.edu
Batuman
Vecihi
V
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D004357:Drug Synergism; D004872:Ergocalciferols / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000187:drug effects; D014807:Vitamin D / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D004872:Ergocalciferols; D014807:Vitamin D; C084656:paricalcitol